Invesco Ltd. Esperion Therapeutics, Inc. Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 493,929 shares of ESPR stock, worth $884,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

493,929

Previous 255,480 93.33%

Holding current value

$884,132

Previous $367,000 31.88%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$0.73 - $1.41 $174,067 - $336,213	238,449 Added 93.33%	493,929 $484,000
Q1 2025 May 12, 2025	BUY	$1.44 - $2.34 $227,011 - $368,893	157,647 Added 161.14%	255,480 $367,000
Q4 2024 Feb 13, 2025	BUY	$1.61 - $3.83 $21,092 - $50,176	13,101 Added 15.46%	97,833 $215,000
Q3 2024 Nov 12, 2024	SELL	$1.61 - $2.73 $3,756 - $6,369	-2,333 Reduced 2.68%	84,732 $139,000
Q2 2024 Aug 13, 2024	BUY	$1.84 - $3.24 $130,104 - $229,097	70,709 Added 432.31%	87,065 $193,000
Q1 2024 May 14, 2024	SELL	$2.02 - $3.02 $13,776 - $20,596	-6,820 Reduced 29.43%	16,356 $43,000
Q4 2023 Feb 12, 2024	BUY	$0.73 - $3.08 $497 - $2,097	681 Added 3.03%	23,176 $69,000
Q3 2023 Nov 13, 2023	SELL	$0.96 - $1.79 $3,315 - $6,182	-3,454 Reduced 13.31%	22,495 $22,000
Q2 2023 Aug 11, 2023	SELL	$1.2 - $1.76 $5,118 - $7,506	-4,265 Reduced 14.12%	25,949 $36,000
Q1 2023 May 12, 2023	BUY	$1.46 - $7.3 $2,341 - $11,709	1,604 Added 5.61%	30,214 $48,000
Q4 2022 Feb 13, 2023	SELL	$5.09 - $8.5 $2.38 Million - $3.98 Million	-467,906 Reduced 94.24%	28,610 $178,000
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $2.59 Million - $3.86 Million	474,610 Added 2166.58%	496,516 $3.33 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $37,210 - $52,032	7,801 Added 55.31%	21,906 $140,000
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $47,110 - $78,423	14,105 New	14,105 $65,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $60,928 - $150,990	-12,667 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $23,099 - $43,530	2,037 Added 19.16%	12,667 $153,000
Q2 2021 Aug 17, 2021	BUY	$19.4 - $28.71 $206,221 - $305,187	10,630 New	10,630 $225,000
Q2 2020 Aug 14, 2020	SELL	$30.04 - $51.31 $3.36 Million - $5.73 Million	-111,725 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $2.93 Million - $7.9 Million	106,957 Added 2243.23%	111,725 $3.52 Million
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $168,787 - $285,221	4,768 New	4,768 $284,000
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $4.55 Million - $6.28 Million	-132,085 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $5.05 Million - $6.59 Million	125,959 Added 2056.14%	132,085 $6.15 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $245,713 - $328,169	6,126 New	6,126 $246,000

Others Institutions Holding ESPR

# of Institutions

197

Shares Held

117M

Call Options Held

171K

Put Options Held

679K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $119M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account